Table 6 Economic impact of HIV and HIV/HCV populations with one comorbidity
HIV+ mono-infected patients | HIV/HCV co-infected patients | Delta between HIV/HCV and HIV+ patients [%] | p-value | |
|---|---|---|---|---|
Mean total cost | € 9,566.95 | € 17,426.32 | 45.10% | < 0.001 |
Mean total cost without HCV therapy cost | € 9,566.95 | € 11,159.68 | 14.27% | 0.001 |
Mean total cost without hospitalization/DH events cost | € 8,759.71 | € 17,425.76 | 49.73% | < 0.001 |
Mean total cost without HCV therapy cost and hospitalization/DH events cost | € 8,759.71 | € 11,159.12 | 21.50% | < 0.001 |
Mean HIV therapy cost | € 7,117.33 | € 9845.34 | 27.71% | < 0.001 |
Mean laboratory tests cost | € 880.19 | € 468.45 | −87.89% | 0.001 |
Mean diagnostic and specialist procedures cost | € 452.52 | € 204.58 | − 121.20% | < 0.001 |
Mean drug cost | € 309.68 | € 640.74 | 51.67% | < 0.001 |